Fuyuan Pharmaceutical: Bemeprost Topical Gel Receives Approval for Clinical Trial Notification

K-LinePoet · 2026-04-09T08:18:06+00:00

Fuyuan Pharmaceutical Announcement: The wholly-owned subsidiary Anhui Fuyuan has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for Beme Prostaglandin Topical Solution. Beme Prostaglandin Topical Solution promotes eyelash growth, making eyelashes longer, thicker, and darker, and is used to treat eyelash hypotrichosis. As of now, Anhui Fuyuan has invested approximately RMB 4.37M in R&D expenses for Beme Prostaglandin Topical Solution.

K-LinePoet

2026-04-09 08:18:06

Fuyuan Pharmaceutical Co., Ltd. announced that its wholly owned subsidiary, Anhui Fuyuan, has received a “Notice of Approval for Drug Clinical Trials” issued and approved by the National Medical Products Administration. The Bimatoprost Ophthalmic Solution for Eyelashes promotes eyelash growth, making eyelashes longer, thicker, and darker, and is used to treat hypotrichosis of the eyelashes. As of now, Anhui Fuyuan has already invested approximately RMB 4.3673 million in R&D expenses for the Bimatoprost Ophthalmic Solution for Eyelashes.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes